Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study
Truman LA., Pekalski ML., Kareclas P., Evangelou M., Walker NM., Howlett J., Mander AP., Kennet J., Wicker LS., Bond S., Todd JA., Waldron-Lynch F.